Yadav et al. [35] further explored the synergistic activity of neratinib in combination with olaparib, a PARP inhibitor, showing that the combination therapy led to improved tumor suppression in HER2/neu+ USC, particularly in tumors resistant to standard chemotherapy. Here, ERBB2 is linked to neoplasm.